Introduction Obstructive sleep apnea (OSA) has been hypothesized to cause a hypersympathetic state, which may be the mechanism for the increased incidence of cardiovascular disease in OSA. However, there is a high prevalence of hyperglycemia in OSA patients, which may also contribute to autonomic dysfunction. Methods Thirty-five patients with OSA and 11 controls with average body mass index (BMI) of 32.0 ± 4.6 underwent polysomnography, glucose tolerance testing, autonomic function tests, lying and standing catecholamines, overnight urine collection, and baseline ECG and continuous blood pressure measurements for spectral analysis. A linear regression model adjusting for age and BMI was used to analyze spectral data, other outcome measures were analyzed with Kruskal-Wallis test. Results Twenty-three OSA patients and two control patients had hyperglycemia (based on 2001 American Diabetes Association criteria). Apnea-hypopnea index (AHI) correlated with total power and low frequency (LF) power (r = 0.138, 0.177, p = 0.031; and r = 0.013) but not with the LF/high frequency (HF) ratio (p = 0.589). Glucose negatively correlated with LF systolic power (r = -0.171, p = 0.038) but not AHI (p = 0.586) and was marginally associated with pnn50, total power, LF, and HF power (p ranged from 0.07 to 0.08). Conclusion These data suggest that patients with OSA and mild hyperglycemia have a trend towards lower heart rate variability and sympathetic tone. Hyperglycemia is an important confounder and should be evaluated in studies of OSA and autonomic function.
Introduction
Obstructive sleep apnea (OSA) is a common disorder affecting 2-4% of the United States population. OSA confers an increased risk in cardiovascular disease and stroke. One mechanism attributed to OSA is hyperactivity of the sympathetic nervous system secondary to chronic intermittent hypoxia occurring during sleep [1] [2] [3] . Multiple studies have demonstrated evidence of hypersympathetic activity and altered autonomic function in patients with sleep apnea [4] [5] [6] .
Obstructive sleep apnea is also highly linked with diabetes mellitus and increased insulin resistance, with a high prevalence of prediabetes and undiagnosed diabetes observed in our previously published cohort [7] as well as other cohorts [8] [9] [10] . In addition, a high number of patients have hyperglycemia which is not detected by fasting glucose [7] . There is significant evidence that even mild hyperglycemia alters autonomic function [11] [12] [13] and that hypersympathetic activity can be observed in early diabetes [14] .
Previous studies of autonomic function in OSA have either not measured glucose (relying on patient self-report of diabetes), or have only used fasting glucose as a screen to rule out hyperglycemia in their cohort. We hypothesized that hyperglycemia may significantly affect measures of autonomic function such as heart rate variability, catecholamine levels, and other autonomic function tests independent of OSA status. We assessed glycemic status, autonomic function and peripheral nerve function in mildly obese patients with a new diagnosis of OSA and followed them after treatment with continuous positive airway pressure (CPAP) to determine if there were any changes after treatment. We report here the initial cross-sectional results.
Methods

Participants
Volunteers with symptoms of disturbed sleep such as snoring and excessive daytime sleepiness were recruited for this longitudinal study. Subjects recruited with normal polysomnograms (PSGs) in the Vanderbilt Sleep Disorders Center were recruited as normal controls. Study participants were between 21 and 75 years of age, with no known history of diabetes or other disorders known to affect the autonomic system. All patients on antihypertensive, anticholinergic, or other medications known to affect autonomic testing were requested to hold medication for at least 3-5 half lives and to withhold caffeine use. Patients unable to hold medications safely for this time period were excluded from the study. To avoid treatment bias, previous treatment of OSA was also an exclusion criteria. Because the study included repeated measurements after CPAP treatment to follow both glucose and autonomic function measures, patients could not be on hypoglycemic medications during the study. Therefore, patients with glucose levels consistent with diabetes were excluded from the study for safety concerns. To avoid obesity as a confounding effect, participants with a body mass index (BMI) of 25-40 were included in the study.
Definitions
Obstructive sleep apnea was defined as an apnea-hypopnea index (AHI) greater than five events/h with either 3% desaturation or EEG arousal present [15] . Glucose status was defined using the 2004 American Diabetes Association criteria (fasting glucose\100 mg/dL normal, 100-125 mg/ dL impaired fasting glucose, [125 mg/dL diabetic, 2-h glucose \140 mg/dL normal, 140-199 mg/dL impaired glucose tolerance, C200 mg/dL diabetic [16] ).
Procedures
This study was approved by the Vanderbilt University Internal Review Board and subjects were consented according to the Declaration of Helsinki. The study was posted on clinicaltrials.gov (NCT00681161). All subjects received a complete physical examination with a detailed neurological exam. Eligible subjects came to the Vanderbilt Clinical Research Center for PSG and for 3-h glucose tolerance testing (OGTT) the following morning. Urine was collected overnight for catecholamine measurement. Participants were kept fasting overnight during their PSG. Study participants with OSA and glucose levels below the diabetic range were invited back for baseline autonomic testing and nerve conduction studies. Study participants were instructed to avoid food and caffeine for 3 h prior to the autonomic testing. Medications known to interfere with autonomic testing were held for 24-48 h prior to testing.
Autonomic evaluation
Recording of ECG, and hemoglobin saturation (SpO 2 ), were measured with a patient monitor with Nellcor technology (Vital-Guard 450C, Ivy Biomedical Systems, Inc., Branford, CT, USA).
Continuous blood pressure was measured by volume clamp method [17] on the middle finger of the non-dominant hand (Nextfin, BMEYE B.V., Amsterdam, The Netherlands) and verified using oscillometric determined brachial BP (Vital-Guard 450C, Ivy Biomedical Systems, Inc.) on the contralateral arm. After a period of at least 30 min in supine position, 10 min of resting supine heart rate and blood pressure data were recorded for spectral analysis. The degree of sinus arrhythmia was assessed during controlled breathing (5 s inhalation and 5 s exhalation (6 cycles/min) during 90 s). The sinus arrhythmia ratio was calculated as the ratio of the longest to the shortest RR interval. Responses of blood pressure fall and heart rate acceleration was determined during 30 s of hyperventilation. A Valsalva maneuver was performed where the patient blows through a mouthpiece connected to a closed pipe with a pressure transducer and a small leakage (22 gauge hole) for 15 s. Blood pressure fall during early phase two, blood pressure recovery during late phase 2, and blood pressure overshoot were determined. The Valsalva ratio of heart rate was calculated. The blood pressure increase to isometric exercise during squeezing a handgrip dynamometer (Model 76618, Lafayette Instrument Co., IN, USA) with the dominant hand at 30% of maximal voluntary contraction for 3 min was determined. A cold pressor test was performed where the patient put the dominant hand into ice water for 1 min and the blood pressure increase at 1 min was recorded.
Orthostatic vital signs were determined by measuring heart rate and brachial blood pressure (Dinamap 1846SX, Critikon, Tampa, FL, USA) on the non-dominant arm and following at least 30 min supine and at 1, 3, 5, and every 5 min until 30 min after standing.
Blood for catecholamine determination during supine and upright were drawn through intravenous catheter on the contra-lateral arm.
QSART QSART testing was performed using the QSweat device (WR Electronics, Rochester, MN, USA) using the technique of Low et al. [18] . Capsules were placed at four standard sites: distal forearm, proximal leg, distal leg, and foot. 10% acetylcholine solution was iontophoresed using a current of 2.0 mA. Results were recorded in microliters of sweat volume. A study was determined to be abnormal if one or more sites were below the fifth percentile for age and gender using previously published normative data, or if there was a proximal distal gradient with a distal site \1/3 the volume of the proximal leg site.
Spectral analysis Signals were digitized at a sampling rate of 500 Hz (DI720USB, DATAQ Instruments, Akron, OH, USA), and then processed with user software written in PV-Wave (Visual Numerics Inc., Houston, TX, USA).
Heart rate variability in the time domain Standard deviation (SD RRI), root mean squared of successive differences of R-R intervals (RMSSD RRI) and percentage of interval changes greater than 50 ms to normal sinus R-R intervals (PNN50) were calculated [19] .
Spectral analysis Beat-to-beat values of detected R-R intervals and BP values were linear interpolated, low-pass filtered (cutoff 0.5 Hz) and re-sampled at 4 Hz. Data segments of 300 s were used for spectral analysis. Linear trends were removed and power spectral density was estimated with the FFT-based Welch algorithm using segments of 256 data points with 50% overlapping and Hanning window [20] . The power in the frequency range of low frequencies (LF 0.04-0.15 Hz) and high frequencies (HF 0.15-0.40 Hz) was calculated following Task Force recommendations [19] .
Baroreflex Gain was defined as the mean magnitude value of the transfer function between BP and RRI in the low-frequency (BRS LF) and high-frequency (BRS HF) band with negative phase and squared coherence value greater than 0.5.
Spontaneous Baroreflex Slope was calculated as the slope of the linear regression line between the systolic BP and the subsequent R-R intervals using sequences defined as an episode of at least three heart beats with more than 0.5 mmHg systolic BP changes and 5 ms R-R interval changes. The averaged value of all slopes with a correlation coefficient greater than 0.85 was calculated for sequences with rising (BRS SEQUP) and falling BP (BRS SEQDOWN) [21] .
Polysomnography
Subjects underwent polysomnography (PSG) in the Vanderbilt Clinical Research Center (CRC). Subjects were studied with standard polysomnographic techniques, using four EEG channels (C3, C4, O1, O2 by the International 10-20 system), three chin electromyogram (EMG) leads, two electrooculogram (EOG) leads, two electrocardiogram (ECG) leads, snoring sound, respiratory effort using the chest and abdomen, airflow at the nose and mouth using thermocouples and nasal pressure cannulas, two bilateral surface EMG electrodes (placed over the anterior tibialis muscles) were recorded. Oxyhemoglobin saturation (SaO 2 ) was monitored by pulse oximetry.
Experienced polysomnographic technologists used standard techniques to score manually all recordings for sleep stages, respiratory events and limb movements. PSG measures followed the American Academy of Sleep Medicine recommendations for sleep staging and respiratory scoring [15] . Studies were then reviewed by one of the authors (KB), a board-certified sleep specialist.
Glucose and insulin regulation
Subjects were kept fasting for a minimum of 8 h before glucose evaluation. Fasting samples were drawn for glucose and insulin levels for the HOMA-IR calculation (homeostasis model approximation for determining insulin resistance, HOMA IR = G 0 I 0 /22.5). Adults \35 with normal BMI and insulin resistance have a HOMA of 1.0, with increasing values indicating greater insulin resistance [23, 24] . A 3-h oral glucose tolerance test (OGTT) with 75 g glucose was performed. Blood samples for glucose and insulin were drawn every 30 min during a 3-h OGTT for a composite insulin sensitivity index (ISI) measurement derived by DeFronzo's calculation: 10,000/ [(G 0 I 0 ) (G avg I avg )] 1/2 . This has been shown to approximate insulin sensitivity calculated from the insulin clamp (R = 0.76). Decreasing values indicate loss of insulin sensitivity [25] . Fasting insulin levels above 40 U/mL were considered abnormal.
Statistical methods
For patient baseline demographics, catecholamine levels, spectral analysis of heart rate variables and autonomic function tests, data were summarized with mean ± standard deviation for continuous variables and with percentages for categorical variables. Unadjusted comparisons between control patients, hyperglycemic, and normoglycemic OSA patients, and between hyperglycemic and normoglycemic OSA patients were conducted using Kruskal-Wallis test and Wilcoxon rank sum test for continuous variables and the Pearson chi-square test for categorical variables.
Linear regression model was used to examine the effects of glucose and AHI on heart rate and blood pressure variability. For each outcome variable, logarithm transformation was used to obtain normally distributed values when needed, and two models were constructed: simple linear model for estimating crude effect and multiple linear regression model for estimating adjusted effect by additionally including prespecified confounding variables age and BMI.
Results
Patient characteristics
Forty-six patients were recruited, 35 patients met diagnostic criteria for OSA and 11 had normal polysomnograms without significant breathing disturbances. Of the 46 patients included in the final analyses, 22 patients had hyperglycemia based on baseline oral glucose tolerance test results (19 had OSA), with either elevated fasting glucose (n = 11 subjects), impaired glucose tolerance (n = 10 subjects), or both (n = 1 subject). There were more women than men in all groups but there were no differences between percentage of women in either OSA or hyperglycemia groups (p = 0.76, 0.92, respectively). There were no significant differences between patients with elevated fasting glucose or impaired glucose tolerance for any variable. Therefore, these groups were combined for all subsequent analyses, we define this combined group the hyperglycemic group.
Patients with OSA (n = 35) were significantly older than the control patients (n = 11, mean ± SD; 46.9 ± 9.2 vs. 36.5 ± 11.7 years, p = 0.009) and were more obese (32.9 ± 4.2 vs. 28.9 ± 3.5 kg/m 2 , p = 0.008), but comparing patients with (n = 22) and without hyperglycemia (n = 24) did not demonstrate any differences in age or BMI (hyperglycemic patient mean age 46.0 ± 8.6 vs. normoglycemic patients age 43.0 ± 12.2 years, p = 0.79, and hyperglycemia patient BMI 32.3 ± 3.8 vs. normoglycemic patient BMI 31.7 ± 4.9 kg/m 2 , p = 0.35) ( Table 1 ). The insulin sensitivity index was not different between hyperglycemic and normoglycemic patients (4.3 ± 2.4 vs. 5.7 ± 2.9, p = 0.10), but HOMA-IR was (2.8 ± 1.4 vs. 2.0 ± 1.5, p = 0.05), although both were significantly different between control patients and OSA patients (ISI 4.6 ± 2.5 vs. 7.7 ± 2.5, p = 0.01 and HOMA-IR 1.7 ± 1.4 vs. 2.7 ± 1.4, p = 0.029). Triglycerides were not significantly higher in the hyperglycemic group (129 ± 78 vs. 124 ± 62.5, p = 0.629) ( Table 2 ).
Autonomic function test results
Autonomic function tests
There were no significant differences between hyperglycemic and normoglycemic patients after analysis of standard autonomic function tests. There was a trend to a lower heart rate among control patients compared to OSA patients (61 ± 12 vs. 68 ± 8 and 70 ± 13) but this was not significant (p = 0.14). There were no differences between healthy controls and OSA patients in baseline heart rate, blood pressure, sinus arrhythmia, heart rate or blood pressure response to Valsalva maneuver, isometric hand grip, or cold pressor test. There was no difference between the groups in sweat volumes at any site (Table 3) .
Heart rate and blood pressure variability
Heart rate variability was calculated from 34 patients who had artifact-free ECG segments while supine before testing began. Age, BMI, glucose, and AHI were analyzed independently and then stepwise. The glucose value used was the 2 h glucose level from their initial OGTT. BMI did not have a significant effect alone on any of the main variables but was kept in the model as a variable of interest. Gender did not have a significant effect on heart rate variability in our data. Therefore, it was not included in the final model. Due to the small number of patient ECG data that could be analyzed, the model was limited to four variables to avoid over fitting of the model. The variables analyzed included age, BMI, AHI and 2 h glucose in mg/dL. Age significantly affected Pnn50, and HF RRI, with a trend in TP RRI and LF RRI. All of the correlations measured were modest with no r 2 value greater than 0.2 but significantly different from zero. Unadjusted, glucose had no effect on any heart rate or blood pressure variables. However, after adjusting for age, BMI, and AHI, there was a correlation with lower LF RRI and TP RRI associated with abnormal glucose (r 2 = -0.19, p = 0.03; r 2 = -0.15, p = 0.04) and trend towards a lower low frequency of systolic blood pressure (r 2 = -0.11, p = 0.06) ( Table 4) . AHI was initially and after adjustment was not associated with any variable except LF RRI (r 2 = 0.13, p = 0.05) ( Table 5) . Table 4 Linear regression analysis of heart rate and blood pressure with glucose before and after adjusting for age, body mass index, and apneahypopnea index Dependent Pnn50 number of normal sinus (NN) intervals with duration greater than 50 ms/number of NN intervals, LF low frequency, RRI R-R interval, HF high frequency, TP total power, rmssd root mean square successive difference in heart period, SYS systolic, BRS lfmn SYS baroreflex gainmean magnitude value of the transfer function between bp and rri in low frequency band,sig sequp and sig seqdown refer to the baroreflex slope of the linear regression line between the systolic bp and subsequent R-R intervals using sequences with more than 0.5 mmHg systolic bp changes and 5 ms R-R interval changes Pnn50 number of normal sinus (NN) intervals with duration greater than 50 ms/number of NN intervals, LF low frequency, RRI R-R interval, HF high frequency, TP total power, rmssd root mean square successive difference in heart period, SYS systolic, BRS lfmn SYS baroreflex gainmean magnitude value of the transfer function between bp and rri in low frequency band, sig sequp and sig seqdown refer to the baroreflex slope of the linear regression line between the systolic bp and subsequent R-R intervals using sequences with more than 0.5 mmHg systolic bp changes and 5 ms R-R interval changes
Discussion
The results of this study suggest that mild hyperglycemia may affect heart rate variability, but does not independently contribute to autonomic dysfunction in patients with OSA. This finding suggests that more severe alterations in glucose may be needed before significant abnormalities are detectable in standard tests of autonomic function. We obtained healthy overweight and obese controls (BMI over 25) to rule out potential effects of obesity on autonomic function [26] . However, either due to the small sample size or the mild OSA present, we did not detect a difference in autonomic function between our OSA patients and control patients which is different from previously published manuscripts. This could be due to the small sample size, but is more likely due to the mild severity of OSA in our patient sample.
There is increasing evidence that impaired glucose tolerance and pre-diabetes may contribute to peripheral nerve dysfunction [27, 28] , and there is some evidence to support development of autonomic changes prior to development of diabetes [12] . A previous study demonstrated lower sweat volumes in asymptomatic patients with impaired glucose tolerance [13] . We did not observe similar findings, which may have been due to several factors, including a younger population and normal neurologic exams with no evidence of peripheral neuropathy, which may indicate that longer periods of sustained hyperglycemia are needed before sweating derangements are evident. It is not clear what degree of hyperglycemia is required or if there are other specific risk factors such as elevated triglycerides which may increase the prevalence of neuropathy in patients with mild hyperglycemia.
Spectral analysis of heart rate variability has become an attractive measure of autonomic function due to the lack of special equipment needed, and ease of obtaining data. Lower heart rate variability detected through analysis of 12-lead ECG data was significantly associated with higher cardiovascular mortality in subjects enrolled in the ACCORD study [29] . The neural control of heart rate is regulated at the sinoatrial node by interaction of sympathetic and vagal efferent discharge. High frequency fluctuations in heart rate have a significant vagal component and are tied to respiratory rate. The low frequency rhythmic fluctuations in heart rate are thought to be secondary to sympathetic modulation, but considerable evidence also suggests a significant vagal component as they are decreased after atropine as well as stellectomy. This ambiguity may limit the interpretation of frequency analyses as they do not always correlate with other measures of autonomic function [30] . However, in many instances, spectral analysis enables evaluation of autonomic input not easily obtained through other methods. Our study suggests that frequency analysis may be a more sensitive tool than standard autonomic function tests in detecting early involvement of the autonomic system compared to other standard autonomic tests. However, our results should be interpreted with caution given the small effect size, and multiple observations reported.
We did not observe evidence of hyper-sympathetic input of heart rate or in any other autonomic test performed, either in hyperglycemic patients or in patients with sleep apnea compared to controls, which may have been due to the mild sleep apnea present in our cohort. Previous studies have demonstrated a dose-dependent effect of OSA [22] . We also analyzed ECG data from our patients while awake for spectral analysis, whereas many of the studies previously performed analyzed ECG data from PSGs. The advantage of this method was to obtain data in a controlled environment, with patients not on any medications known to affect heart rate or autonomic function; this is not possible in ECG data abstracted from PSGs performed in large sleep laboratories.
We again have shown that approximately 50% of the OSA patients had hyperglycemia, and a significant correlation between hyperglycemia and sleep apnea. Hyperglycemia is highly prevalent in patients with sleep apnea, and conversely, sleep apnea is highly prevalent in diabetic populations independent of obesity and age. It is not known whether the presence of OSA is a risk factor for other diabetic complications.
In conclusion, mild hyperglycemia present in OSA may have an early effect on heart rate variability, and may contribute to autonomic dysfunction observed in these patients. However, major autonomic dysfunction consistent with diabetes was not observed in our hyperglycemic OSA patients. Future studies are needed to determine if measures of heart rate variability alone are superior to other measures of autonomic function in this cohort.
